Interventional News’ top 10 most popular stories of October 2021   

297

Interventional News Top 10 OctoberOctober’s top 10 features an interview with Maureen Kohi (Chapel Hill, USA), the chair and professor of Radiology (University of North Carolina), and the chief of Interventional Radiology (University of California, San Francisco, USA). The US Food and Drug Administration (FDA) granted Varian breakthrough device designation for its Embozene microspheres for genicular artery embolization (GAE), which has attracted many readers, as has issue 83 of Interventional News. 

1) Maureen Kohi 

“I strongly believe that you cannot be what you cannot see. If you want more women or under-represented minorities (URMs) to enter the field and be at the table, then we need more women and URM leaders in the field,” Maureen Kohi (Chapel Hill, USA). 

2Varian receives FDA breakthrough device designation for its Embozene microspheres 

Varian, a Siemens Healthineers company, announced that the US Food and Drug Administration (FDA) has granted the company breakthrough device designation for its Embozene microspheres for genicular artery embolization (GAE) for symptomatic knee osteoarthritis. 

3) Head-to-head trial shows superiority of FemoSeal over ProGlide for peripheral interventions 

Results of the randomised, prospective, multicentre STEP trial show that the FemoSeal vascular closure system (Terumo) is superior to the Perclose ProGlide suture-mediated closure system (Abbott) in peripheral arterial disease (PAD) patients in terms of technical success using a retrograde femoral puncture. Bahaa Nasr (Brest University Hospital, Brest, France) presented the late-breaking data at Paris Vascular Insights (PVI) 2021 (21–23 October, Paris, France), concluding that FemoSeal should be used in PAD patients undergoing lower limb arterial endovascular treatment, especially if they are discharged on the same day as their surgery. 

4) EMINENT one-year results show “superior” primary patency rate for Eluvia DES compared to bare metal stents 

One-year results presented at Vascular Interventional Advances (VIVA) 2021 (5–7 October, Las Vegas, USA) from the EMINENT trial demonstrated the superiority of the Eluvia drug-eluting stent (DES) system (Boston Scientific) compared to self-expanding bare metal stents for the treatment of patients with peripheral arterial disease (PAD) with superficial femoral artery (SFA) or popliteal artery lesions up to 210mm in length, the principal investigator (PI) said. The study enrolled 775 patients, making it the largest randomised trial of a DES for the treatment of PAD to date, Boston Scientific said in a press release.  

5)The WavelinQ™ EndoAVF System takes an innovative approach in creating endovascular AV fistulas for dialysis patients 

Rethink fistula creation and maintenance with Tobias Steinke, Ounali Jaffer, Panagiotis Kitrou and Robert Jones in this four-page advertorial.  

This advertorial is ONLY available to read in selected countries and geographies. This advertorial, sponsored by BD, is intended for readers in the EMEA region only. 
 

6)The future of procedural training is virtual 

In the wake of the COVID-19 pandemic, the world of education went virtual. John Rundback (Advanced Interventional & Vascular Services LLP and American Endovascular & Amputation Prevention PC in Clifton, USA), who has been involved in interventional device education for more than 25 years, believes virtual procedural training is here to stay. In this interview, Rundback details how procedural training has adapted and is thriving in its new digital setting, with available systems offering increasingly immersive learning environments available to an international cohort of students. He also predicts an 80:20 split between virtual and in-person training in the future.  

7)Target lesion revascularisation in the firing line 

Is target lesion revascularisation (TLR) a meaningful clinical endpoint for research or should it be “tossed as a legitimate endpoint for peripheral vascular disease treatment success in US FDA [Food and Drug Administration] approval trials?” Recent keynote presentations and conference debate on appropriate care for peripheral vascular disease leave overuse of interventional therapy, particularly for claudication, staring down the end of a barrel. They also trigger a conversation around TLR becoming a target in and of itself. 

8)Interventional News issue 83—September 2021 Edition 

Interventional News 83 highlights: 

  • CAVA RCT delivers powerful evidence supporting use of PORTs to supply systemic chemotherapy 
  • Wesley Hospital becomes first in Australia to achieve IASIOS accreditation in historic global milestone for CIRSE 
  • International training and outreach in the pandemic era 
  • Target lesion revascularisation in the firing line 
  • Profile: Maureen Kohi 
  • Advertorial: Reliability, ease-of-us, and availability have made SkaterTM drainage catheters a go-to product 
  • No working vein, no gain: New devices gather data on boosting vein enlargement to aid functional AVF creation 

9) Sirtex Medical and China Grand Pharmaceutical announce successful first administration of SIR-Spheres Y-90 resin microspheres in China 

Sirtex Medical (Sirtex) has announced that the first procedure of selective internal radiation therapy (SIRT) using SIRSpheres Y-90 resin microspheres in China was successfully performed for a patient with hepatocellular carcinoma (HCC) on 28 September 2021. The milestone was reached with the support of Sirtex shareholder China Grand Pharmaceutical and Healthcare Holdings Limited. 

10)ECLIPSE shows cryoablation effective for local control of pulmonary long-term metastatic tumours 

Cryoablation is effective for local tumour control in patients with pulmonary metastatic disease. Within the ECLIPSE study, cryoablation had no significant impact on the patient’s quality of life (QoL), with the patient disease-specific survival rate remaining higher than the overall survival rate at both three and five years of follow-up.  

 


LEAVE A REPLY

Please enter your comment!
Please enter your name here